Since HO-1 contributes to chemo resistance in cancer cells [20] and is a potential cancer therapeutic target [21, 22], the attenuation of DHA-induced HO-1 expression levels by Sorafenib could lead to an enhanced cytotoxicity toward cancer cells. This evidence concerns the gene HMOX1 and cancer.